Abstract |
Current treatment of rheumatoid arthritis (RA) is limited by relative shortage of treatment targets. HM-3 is a novel anti-RA polypeptide consisting of 18 amino acids with integrin αVβ3 and α5β1 as targets. Previous studies confirmed that HM-3 effectively inhibited the synovial angiogenesis and the inflammatory response. However, due to its short half-life, the anti-RA activity was achieved by frequent administration. To extend the half-life of HM-3, we designed a fusion protein with name HM-3-Fc, by combination of modified Fc segment of immunoglobulin 4 ( IgG4) with HM-3 polypeptide. In vitro cell experiments demonstrated that HM-3-Fc inhibited the proliferation of splenic lymphocytes and reduced the release of TNF-α from macrophages. The pharmacodynamics studies on mice paw in Collagen-Induced Arthritis (CIA) model demonstrated that HM-3-Fc administered once in 5 days in the 50 and 25 mg/kg groups, or once in 7 days in the 25 mg/kg group showed a better protective effect within two weeks than the positive control adalimumab and HM-3 group. Preliminary pharmacokinetic studies in cynomolgus confirmed that the in vivo half-life of HM-3-Fc was 15.24 h in comparison with 1.32 min that of HM-3, which demonstrated that an Fc fusion can effectively increase the half-life of HM-3 and make it possible for further reduction of subcutaneous injection frequency. Fc-HM-3 is a long-acting active molecule for RA treatment.
|
Authors | Ruijing Huang, Jian Li, Yibo Wang, Lihua Zhang, Xiaohui Ma, Hongyu Wang, Wenlei Li, Xiaodan Cao, Hanmei Xu, Jialiang Hu |
Journal | International journal of molecular sciences
(Int J Mol Sci)
Vol. 19
Issue 9
(Sep 10 2018)
ISSN: 1422-0067 [Electronic] Switzerland |
PMID | 30201867
(Publication Type: Journal Article)
|
Chemical References |
- Immunoglobulin Fc Fragments
- Integrin alpha5beta1
- Integrin alphaVbeta3
- Integrins
- Peptides
- Recombinant Fusion Proteins
- TNF protein, human
- Tumor Necrosis Factor-alpha
- Adalimumab
|
Topics |
- Adalimumab
(administration & dosage, pharmacology)
- Animals
- Arthritis, Experimental
(prevention & control)
- Cell Proliferation
(drug effects)
- Cells, Cultured
- Disease Models, Animal
- Half-Life
- Humans
- Immunoglobulin Fc Fragments
(administration & dosage, pharmacology)
- Integrin alpha5beta1
(antagonists & inhibitors)
- Integrin alphaVbeta3
(antagonists & inhibitors)
- Integrins
(antagonists & inhibitors)
- Lymphocytes
(cytology, drug effects)
- Mice
- Peptides
(administration & dosage, pharmacology)
- Recombinant Fusion Proteins
(administration & dosage, pharmacology)
- Spleen
(immunology)
- Tumor Necrosis Factor-alpha
(metabolism)
- Zebrafish
|